Retrospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jun 7, 2019; 25(21): 2650-2664
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2650
Table 1 Demographic and clinical characteristics of the study and validation groups, n (%)
VariableStudy group (n = 189)Validation group (n = 109)P-value
POPF0.976
No POPF117 (61.9)68 (62.4)
Grade A (BL)34 (18.0)18 (16.5)
Grade B32 (16.9)20 (18.3)
Grade C6 (3.2)3 (2.8)
Age (yr)61.8 ± 9.962.4 ± 10.30.650
Sex0.284
Male116 (61.4)60 (55.0)
Female73 (38.6)49 (45.0)
Surgery0.595
PD98 (51.9)60 (55.0)
PPPD91 (48.1)49 (45.0)
BMI (kg/m2)22.1 ± 2.922.4 ± 2.90.431
Diabetes mellitus0.164
Yes31 (16.4)25 (22.9)
No158 (83.6)84 (77.1)
Location of tumor0.493
Pancreas105 (55.6)65 (59.6)
Non-pancreas84 (44.4)44 (40.4)
Pathologic type0.834
Benign11 (5.8)7 (6.4)
Pancreatic myxoid cystadenoma7 (3.7)5 (4.6)
Pancreatic serous cystadenoma4 (2.1)2 (1.8)
Malignant178 (94.2)102 (93.6)
Pancreatic cancer92 (48.7)56 (51.4)
Biliary duct cancer29 (15.3)21 (19.3)
Ampullary cancer33 (17.5)16 (14.7)
Duodenal cancer24 (12.7)9 (8.3)
Preoperative STB (μmol/L)111.4 ± 120.4116.0 ± 144.90.767
Preoperative pre-albumin (mg/L)141.2 ± 57.1142.4 ± 56.80.861
Preoperative serum albumin (g/L)38.4 ± 5.737.5 ± 4.70.137
Preoperative serum globulin (g/L)26.9 ± 4.227.2 ± 4.90.606
Preoperative hemoglobin (g/L)121.4 ± 19.9119.9 ± 19.50.533
Preoperative white blood cells (109/L)7.0 ± 8.16.4 ± 2.60.465
Preoperative platelets (109/L)233.7 ± 78.5237.6 ± 73.70.671
Pancreatic texture0.725
Soft81 (42.9)49 (45.0)
Hard108 (57.1)60 (55.0)
Main pancreatic duct diameter (mm)3.1 ± 1.03.2 ± 1.10.496
Biliary tract compression23 (12.2%)15 (13.8)0.691
Pancreaticojejunostomy anastomosis0.061
Duct-to-mucosa153 (81.0)78 (71.6)
Dunking method36 (19.0)31 (28.4)
Pancreatic duct stent0.735
Internal stent85 (45.0)50 (45.9)
External stent68 (36.0)35 (32.1)
None36 (19.0)24 (22.0)
Vascular invasion0.483
Yes32 (16.9)22 (20.2)
No157 (83.1)87 (79.8)
Operative time (min)269.5 ± 70.3255.4 ± 64.70.088
Estimated blood loss (mL)320.3 ± 269.3326.6 ± 267.50.846
Serum albumin POD 1 (g/L)33.01 ± 5.433.4 ± 5.70.623
Serum globulin on POD 1 (g/L)23.4 ± 10.926.1 ± 27.20.233
Hemoglobin on POD 1 (g/L)112.0 ± 16.8112.4 ± 15.80.849
Table 2 Demographic and clinical characteristics of the clinically relevant postoperative pancreatic fistula and non-clinically relevant postoperative pancreatic fistula groups, n (%)
Variablenon-CR-POPF (n = 237)CR-POPF (n = 61)P-value
Age (yr)61.8 ± 10.162.2 ± 9.40.804
Sex0.095
Male135 (57.0)41 (67.2)
Female102 (43.0)20 (32.8)
Surgery0.445
PD123 (51.9)35 (57.4)
PPPD114 (48.1)26 (42.6)
BMI (kg/m2)22.0 ± 2.922.5 ± 2.80.352
Diabetes mellitus0.351
Yes42 (17.7)14 (23.0)
No195 (82.3)47 (77.0)
Location of tumor0.131
Pancreas130 (54.9)40 (65.6)
Non-pancreas107 (45.1)21 (34.4)
Pathologic type0.428
Benign13 (5.5)5 (8.2)
Malignant224 (94.5)56 (91.8)
Preoperative STB (μmol/L)106.0 ± 120.0132.8 ± 120.90.221
Preoperative pre-albumin (mg/L)143.1 ± 56.2133.7 ± 60.70.364
Preoperative serum albumin (g/L)39.1 ± 5.435.9 ± 6.30.002
Preoperative serum globulin (g/L)26.9 ± 4.327.2 ± 3.30.675
Preoperative hemoglobin (g/L)122.1 ± 18.3118.6 ± 25.20.339
Preoperative white blood cells (109/L)7.0 ± 8.96.7 ± 2.10.833
Preoperative platelets (109/L)236.3 ± 83.5223.2 ± 54.10.358
Pancreatic texture< 0.001
Soft80 (33.8)50 (82.0)
Hard157 (66.2)11 (18.0)
Main pancreatic duct diameter (mm)3.2 ± 1.02.6±0.70.001
Biliary tract compression31 (13.1)7 (11.5)0.738
Pancreaticojejunostomy anastomosis0.201
Duct-to-mucosa180 (75.9)51 (83.6)
Dunking method57 (24.1)10 (16.4)
Pancreatic duct stent0.052
Internal stent99 (41.8)36 (59.0)
External stent88 (37.1)15 (24.6)
None50 (21.1)10 (16.4)
Vascular invasion0.272
Yes40 (16.9)14 (23.0)
No197 (83.1)47 (77.0)
Operative time (min)267.9 ± 68.7275.9 ± 76.90.531
Estimated blood loss (mL)287.4 ± 229.3451.3 ± 365.10.001
Serum albumin POD 1 (g/L)33.03 ± 5.232.9 ± 5.90.918
Serum globulin on POD 1 (g/L)23.5 ± 11.923.0 ± 4.90.832
Hemoglobin on POD 1 (g/L)111.2 ± 17.3114.9 ± 14.30.236
Table 3 Univariate and multivariate analyses of predictive factors for clinically relevant pancreatic fistula in the study group (n = 189)
FactorUnivariate analysis
Multivariate analysis
OR95%CIP-valueOR95%CIP-value
Patient characteristics
Age (≥ 65 yr/< 65 yr)1.070.52-2.210.848
Sex (male/female)0.580.27-1.140.107
BMI (≥ 24/< 24 kg/m2)0.990.44-2.220.983
Diabetes mellitus (yes/no)0.730.26-2.040.546
Preoperative status
Location of tumor (pancreas/non-pancreas)0.660.32-1.350.256
Preoperative STB (≥ 22 μmol/L vs < 22 μmol/L)1.070.50-2.300.857
Preoperative pre-albumin (≥ 170 mg/L vs < 170 mg/L)0.840.38-1.880.672
Preoperative serum albumin (≥ 35 g/L vs < 35 g/L)0.190.09-0.40< 0.0010.920.85-0.990.032
Preoperative serum globulin (≥ 22 g/L vs < 22 g/L)2.590.58-11.650.201
Preoperative hemoglobin (≥ 110 g/L vs < 110 g/L)0.610.27-1.400.241
Preoperative WBC (≥ 3.5 × 109/L vs < 3.5 × 109/L)0.750.14-3.850.725
Preoperative PLT (≥ 150 × 109/L vs < 150 × 109/L)1.080.74-3.410.898
Intraoperative status
Pancreatic texture (hard/soft)0.050.02-0.12< 0.0010.250.10-0.640.004
Surgery (PD/PPPD)1.040.51-2.120.914
Pathologic type (benign/malignant)2.420.67-8.740.166
Main pancreatic duct diameter (≥ 3 mm vs < 3 mm)0.260.12-0.54< 0.0010.500.27-0.930.029
Pancreaticojejunostomy anastomosis (duct-to-mucosa/dunking method)0.580.25-1.340.202
Pancreatic duct stent (yes/no)1.710.62-4.730.301
Vascular invasion (yes/no)0.900.34-2.380.834
Operative time (≥ 300 min vs < 300 min)0.740.36-1.650.466
Estimated blood loss (≥ 500 mL vs < 500 mL)3.631.65-7.980.0011.0021.001-1.0030.006
Postoperative status
Serum albumin POD 1 (≥ 35 g/L vs < 35 g/L)0.740.34-1.650.466
Serum globulin POD 1 (≥ 22 g/L vs < 22 g/L)0.930.46-1.910.851
Hemoglobin POD 1 (≥ 110 g/L vs < 110 g/L)2.070.96-4.460.062
Table 4 Risk scoring system for clinical relevant pancreatic fistula
Risk factorPoints contributed
Texture of pancreas (3 points)
Hard0 points
Soft3 points
Main pancreatic duct diameter (2 points)
≥ 3 mm0 points
< 3 mm2 points
Preoperative serum albumin (2 points)
≥ 35 g/L0 points
30-35 g/L1 point
< 30 g/L2 points
Estimated blood loss (3 points)
< 500 mL0 points
500-1000 mL1 point
≥ 1000 mL3 points
Sun score10 points
High-risk score4-10 points
Low-risk score0-3 points
Table 5 Correlation between risk score and postoperative pancreatic fistula
Study group (n = 189)
Validation group (n = 109)
All (n = 298)
Risk score
Risk score
Risk score
POPF gradeLowHighLowHighLowHigh
No POPF972060815728
Grade A (BL)18161172923
Grade B7255151240
Grade C060309
CR-POPF rate5.7%46.3%6.6%54.6%6.1%49.0%
r = 0.542r = 0.586r = 0.557
P < 0.001P < 0.001P < 0.001
Table 6 Relationship between postoperative drain amylase levels and clinically relevant postoperative pancreatic fistula
Low risk group
High risk group
P-valueAUCCut-off valueP-valueAUCCut-off value
POD 1> 0.05----0.0010.850921.7 U/L
POD 30.0030.8594021.5 U/L0.05----
POD 50.0420.7484533.5 U/L0.05----